Company Structure and Subsidiaries - Sichuan ZiTongGong Pharmaceutical Co., Ltd. registered a new wholly-owned subsidiary, Chengdu Majiazi Biotechnology Co., Ltd., with a registered capital of 6 million yuan in July 2022[6]. - The company has completed the registration of its updated business scope, which now includes medical research and development, and traditional Chinese medicine planting and acquisition[30]. - The company established a wholly-owned subsidiary, Chengdu Majiazi Biotechnology Co., Ltd., in June 2022, with a registered capital of RMB 6 million, which has been included in the consolidated financial statements since its establishment[109]. Financial Performance - The company's operating revenue for 2022 was approximately ¥442.16 million, representing a 4.25% increase from ¥424.13 million in 2021[33]. - The net profit attributable to shareholders for 2022 was approximately ¥102.07 million, a 27.42% increase compared to ¥80.11 million in 2021[33]. - The gross profit margin for 2022 was 79.96%, slightly down from 80.54% in 2021[33]. - The basic earnings per share for 2022 was ¥0.70, up 9.38% from ¥0.64 in 2021[33]. - The company's net profit margin improved, with a net profit growth rate of 28.26% compared to 26.52% in 2021[39]. - Operating cash flow increased by 80.58% to ¥107,634,514.09 from ¥59,605,333.33 in 2021[38]. - The company's total assets increased by 8.44% to ¥842,184,856.01 compared to ¥776,603,783.55 at the end of 2021[35]. - The company's total liabilities increased by 0.48% to ¥130,319,447.71 from ¥129,700,690.14 in 2021[35]. - The company's net assets attributable to shareholders increased by 10.18% to ¥707,835,828.64 compared to the end of the previous year[53]. - The company reported a total non-recurring gains and losses of ¥27,537,826.57 in 2022, significantly higher than ¥8,618,953.83 in 2021[44]. Research and Development - The company plans to focus on the development of new drugs in the fields of the nervous system, digestive system, and endocrine system[14]. - The company has a total of 96 drug production approvals, focusing on neurological and digestive system medications[49]. - The company is actively conducting market research to identify new R&D projects, as no new projects have been initiated during the reporting period[94]. - The company has established collaborations with various institutions for R&D projects, ensuring that all intellectual property rights belong to the company[100]. - The company holds a total of 71 patents, an increase from 44 in the previous period[97]. - The R&D team consists of over 50 personnel, with a significant proportion holding advanced degrees and professional titles, enhancing the company's innovation capabilities[196]. - The company's R&D investment for the year 2022 was ¥26,605,451.79, accounting for 6.02% of its revenue[197]. Market and Product Strategy - The company plans to expand its product offerings in the endocrine system medication area as a future development focus[49]. - The company is focusing on expanding its traditional Chinese medicine (TCM) product line, including unique proprietary products such as Dongfang Weiyao capsules and Ma Jia Zi capsules, with ongoing clinical trials for new drugs[119]. - The company plans to accelerate the research and development of innovative drugs, particularly the anti-cancer proprietary Chinese medicine Ma Jia Zi capsules, and enhance its patent application efforts[123]. - The company plans to focus on promoting the chemical drug "阿咖酚散" and the raw material "人工牛黄" as key products in its future product strategy[187]. Risks and Challenges - The company faces risks related to accounts receivable management, which may increase if major clients experience adverse business conditions[14]. - The company is subject to risks from changes in government policies affecting the pharmaceutical industry, which could impact operational models and business strategies[16]. - The company is addressing the risk of new product development failures by optimizing its product pipeline and collaborating with renowned universities and research institutions[127]. - The company is facing risks related to increasing promotional expenses as it expands into the specialized medication market, which may impact profit margins[128]. Corporate Governance and Compliance - The company has engaged Ping An Securities as its continuous supervision sponsor since August 2021[29]. - The company has implemented changes in accounting policies effective January 1, 2022, related to the accounting treatment of sales of products produced during the trial operation phase, with no impact on the financial statements[106]. - The company has committed to compliance and governance improvements following regulatory measures taken by the Sichuan Securities Regulatory Bureau[142]. - The company has established a marketing supervision team to review service providers and ensure compliance with internal controls[141]. Social Responsibility and Environmental Impact - The company actively participates in poverty alleviation and rural revitalization efforts, including the establishment of a traditional Chinese medicine planting experimental base in Huangzhuoqiao Village, which contributes to local economic development[110]. - The company emphasizes corporate social responsibility, maintaining employee rights and welfare, and has been recognized as a "Model Employee Home" in Neijiang City[111]. - The company has implemented strict environmental protection measures, including wastewater treatment that meets park standards, with a total wastewater discharge of 3,500 m³/d from various sources[115]. - The company has achieved a dust removal efficiency of over 99% in its production facilities, ensuring compliance with air quality standards[115]. Shareholder Information - The controlling shareholder, Tang Xi, directly holds 22.47% of the shares and indirectly controls an additional 1.45%, totaling 23.92%[150]. - The total number of unrestricted shares increased from 38,484,135 (52.52%) to 114,829,761 (78.35%) during the reporting period[146]. - The number of shareholders holding more than 5% of shares totaled 10, with a combined holding of 50.04%[149]. Future Outlook - The pharmaceutical industry in China is expected to maintain an upward trend, driven by factors such as aging population and increased health spending, despite facing downward pressure in 2022[118]. - The company aims to implement a "one body, two wings" strategy during the 14th Five-Year Plan, focusing on pharmaceutical manufacturing while enhancing brand operations and investment[122]. - The company will closely monitor industry policy changes and adjust its operational strategies accordingly to maintain steady product growth[183].

证券代码：832566 证券简称：梓橦宫 公告编号：2023-045 四川梓橦宫药业股份有限公司 2022 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 （二）会议召开地点 本次年度报告业绩说明会将采用网络方式召开，投资者可登陆全景网"投资 者关系互动平台"（http://ir.p5w.net）参与本次年报业绩说明会。 三、 参加人员 公司董事长：唐铣先生； 公司董事、总经理：李云先生； 公司董事、财务总监：段立平女士； 公司董事、董事会秘书：曾培玉女士； 保荐代表人：邹文琦先生。 四、 投资者参加方式 本次说明会采用网络方式召开。 为充分听取投资者意见，提升交流的针对性，现就本公司 2022 年年度报告 业绩说明会提前向投资者公开征集问题。投资者可于 2023 年 5 月 18 日（周四） 15:00 前访问（http://ir.p5w.net/zj/）或扫描下方二维码，进入问题征集专 题页面进行提问。公司将在 2022 年年度报告业绩说明会上，对投资者普遍关注 的问题 ...

Financial Performance - Operating revenue for Q1 2023 was CNY 90,389,582.56, a decrease of 11.37% from CNY 101,980,920.45 in Q1 2022[10] - Net profit attributable to shareholders decreased by 43.07% to CNY 16,169,467.62, down from CNY 28,401,290.54 in the same period last year[10] - Basic earnings per share fell by 42.11% to CNY 0.11, compared to CNY 0.19 in Q1 2022[11] - Total operating revenue for Q1 2023 was CNY 90,389,582.56, a decrease of 11.3% compared to CNY 101,980,920.45 in Q1 2022[34] - Net profit for Q1 2023 was CNY 16,151,291.15, a decline of 42.4% from CNY 28,044,360.11 in Q1 2022[35] - The total comprehensive income for the period was CNY 16,441,167.59, down from CNY 30,951,503.77, indicating a decrease of approximately 46.9%[40] Assets and Liabilities - Total assets increased by 2.38% to CNY 862,220,151.64 as of March 31, 2023, compared to CNY 842,184,856.01 at the end of 2022[10] - The total assets as of March 31, 2023, amounted to CNY 862,220,151.64, an increase from CNY 842,184,856.01 as of December 31, 2022, reflecting a growth of approximately 2.4%[26] - The total current assets increased to CNY 579,259,936.26 from CNY 557,264,782.89, representing a growth of about 3.5%[26] - The company's total liabilities increased to CNY 77,230,417.99 from CNY 72,205,720.23, which is an increase of about 7%[27] - Total liabilities as of March 31, 2023, were CNY 116,824,723.37, compared to CNY 112,257,024.29 at the end of 2022, reflecting a rise of 4.5%[32] - Shareholders' equity totaled CNY 765,567,210.70 as of March 31, 2023, up from CNY 749,126,043.11 at the end of 2022, indicating a growth of 2.2%[32] Cash Flow - Cash flow from operating activities increased by 3.01% to CNY 28,875,466.97, compared to CNY 28,032,913.92 in the previous year[11] - Cash inflows from operating activities totaled CNY 121,311,583.13, compared to CNY 132,168,802.79 in Q1 2022, a decrease of about 8.2%[41] - Cash outflows from operating activities were CNY 92,436,116.16, down from CNY 104,135,888.87, reflecting a decrease of approximately 11.2%[41] - The net cash flow from operating activities was CNY 28,875,466.97, slightly up from CNY 28,032,913.92 in the previous year, an increase of about 3%[41] - Cash and cash equivalents increased by 58.30% to CNY 33,366,980, primarily due to an increase in bank deposits[12] - Cash and cash equivalents increased to CNY 90,291,486.02 from CNY 56,496,354.37, representing a growth of 59.9%[30] - Cash and cash equivalents at the end of Q1 2023 amounted to CNY 83,193,198.21, down from CNY 130,939,165.17 at the end of Q1 2022, a decrease of 36.4%[45] - The net increase in cash and cash equivalents for Q1 2023 was CNY 29,934,053.59, compared to CNY 12,386,162.41 in Q1 2022, showing an increase of 142.5%[45] Investments and Expenses - Investment income decreased by 46.29% to CNY 77,350, primarily due to lower interest rates on bank wealth management products[12] - Research and development expenses were CNY 313,933.38, down from CNY 375,692.08, indicating a reduction of approximately 16.4%[39] - Sales expenses decreased to CNY 47,476,689.39 from CNY 57,230,035.56, a decline of about 17% year-over-year[39] - Total cash inflow from investment activities was CNY 434,477,811.62, down from CNY 521,711,482.17 in the same period last year, representing a decline of 16.7%[45] - Cash outflow for investment activities totaled CNY 433,280,325.12, compared to CNY 541,951,835.00 in Q1 2022, indicating a decrease of 20.1%[45] - Net cash flow from investment activities was CNY 1,197,486.50, recovering from a negative cash flow of CNY 20,240,352.83 in Q1 2022[45] Shareholder Information - The proportion of major shareholders holding more than 5% of shares decreased from 73,204,074 to 68,554,971, a reduction of approximately 6.5%[19] - The largest shareholder, Tang Xi, holds 22.47% of the shares, with no change from the previous period[19] Other Information - The company has no significant litigation or arbitration matters reported during the period[22] - There were no major acquisitions or asset sales reported in the current quarter[22] - The company reported a decrease in accounts receivable from CNY 114,873,350.92 to CNY 100,781,754.18, a decline of about 12.3%[26] - The total non-current assets slightly decreased from CNY 284,920,073.12 to CNY 282,960,215.38, a reduction of approximately 0.7%[27] - Deferred income tax liabilities decreased to CNY 793,160.90 from CNY 990,966.12, a reduction of 20.0%[32]

Company Structure and Subsidiaries - Sichuan ZiTongGong Pharmaceutical Co., Ltd. registered a new subsidiary, Chengdu Majiazi Biotechnology Co., Ltd., with a registered capital of 6 million RMB in July 2022[6]. - The registered capital of the company increased to 146.56 million RMB in July 2022[6]. - The company completed the registration of its business scope change on April 14, 2023, allowing for broader operational activities[30]. - The total share capital of the company is 146,561,080 shares, with no preferred shares issued[27]. - The company established a wholly-owned subsidiary, Chengdu Majiazi Biotechnology Co., Ltd., in June 2022, with a registered capital of RMB 6 million, fully controlled by the company[109]. Financial Performance - The company's operating revenue for 2022 was approximately RMB 442.16 million, representing a 4.25% increase compared to RMB 424.13 million in 2021[33]. - The net profit attributable to shareholders for 2022 was approximately RMB 102.07 million, an increase of 27.42% from RMB 80.11 million in 2021[33]. - The gross profit margin for 2022 was 79.96%, slightly down from 80.54% in 2021[33]. - The basic earnings per share for 2022 was RMB 0.70, reflecting a 9.38% increase from RMB 0.64 in 2021[33]. - The net profit after deducting non-recurring gains and losses was approximately RMB 78.76 million for 2022, an increase of 8.15% from RMB 72.82 million in 2021[33]. - Total assets increased by 8.44% to ¥842,184,856.01 compared to ¥776,603,783.55 at the end of 2021[35]. - Operating cash flow increased by 80.58% to ¥107,634,514.09 from ¥59,605,333.33 in 2021[38]. - The company reported a gross profit margin of 15.02% for the year, slightly up from 15.19% in the previous year[40]. - The net asset attributable to shareholders increased by 10.18% to ¥707,835,828.64 from ¥642,408,855.38 in 2021[35]. Risks and Challenges - The company reported a risk of increasing accounts receivable due to business expansion, which may lead to bad debts if major clients face adverse conditions[14]. - The company faces new product development risks, as the entire process requires significant funding and has a high failure rate[14]. - The company is exposed to risks from changes in drug pricing policies, which could negatively affect profitability[15]. - The company has maintained a strict compliance with national laws and regulations, ensuring no significant violations occurred during its operations[53]. - The company is closely monitoring industry policy changes and will actively respond to these changes to ensure compliance and growth[59]. Research and Development - The company plans to focus on the development of drugs for the nervous system, digestive system, and endocrine system[49]. - The company is committed to enhancing its research and development capabilities, particularly in the areas of neuropsychiatric and digestive system medications, while managing the risks associated with new product development[126]. - The company invested ¥26,605,451.79 in R&D during the reporting period, accounting for 6.02% of its revenue[194]. - The main R&D projects include the development of original Chinese medicine, chemical generics, consistency evaluation of major products, and secondary development of exclusive traditional Chinese medicine[194]. - The company has established collaborations with various institutions for R&D projects, ensuring that all intellectual property rights belong to the company[100]. Marketing and Sales - The company is increasing marketing expenditures to expand its specialized drug market, which may impact profit margins[15]. - The company's sales model for prescription drugs primarily involves academic promotion and distribution through large pharmaceutical distribution companies[53]. - Major customers accounted for 61.55% of total sales, with the largest customer, China National Pharmaceutical Group, contributing CNY 127,302,792.78, or 28.79% of total sales[77]. - The company plans to enhance its marketing management system and expand sales channels while increasing R&D investment to enrich its product line[59]. Corporate Social Responsibility - The company actively participates in poverty alleviation and rural revitalization efforts, continuing its support in Huangzhuoqiao Village, contributing to local economic development[110]. - The company emphasizes corporate social responsibility, maintaining employee rights and welfare, and has established a union to facilitate communication with employees[111]. - The company has implemented strict environmental protection measures, including wastewater treatment and air quality management, ensuring compliance with national standards[115]. Shareholder and Capital Management - The company completed a cash dividend distribution of 36,640,270.00 yuan and increased its total share capital from 73,280,540 shares to 146,561,080 shares[143]. - The top ten shareholders collectively hold 50.04% of the company's shares, indicating a concentrated ownership structure[146]. - The company has implemented strict management protocols for the use of raised funds, including dedicated accounts and oversight measures[152]. - The actual controller and major shareholders have fulfilled commitments regarding share lock-up and stability measures[138]. Future Outlook - The company plans to expand its presence in the health sector by integrating upstream and downstream resources[87]. - The company aims to implement a "one body, two wings" strategy during the 14th Five-Year Plan, focusing on pharmaceutical manufacturing and brand operation to drive growth[122]. - The company’s future outlook includes continued investment in new product development and market expansion strategies[152]. - The pharmaceutical industry in China is expected to maintain an upward trend, driven by factors such as aging population and increased health spending[118].

证券代码：832566 证券简称：梓橦宫 公告编号：2023-009 四川梓橦宫药业股份有限公司 2022 年年度业绩快报公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示：本公告所载 2022 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2022 年年度报告中披露的数据为准，提请投 资者注意投资风险。 一、2022 年年度主要财务数据和指标 单位：元 三、风险提示 本公告所载为公司财务部门初步预测数据，尚未经会计师事务所审计，不构 成公司对投资者的业绩承诺，最终数据以公司正式披露的 2022 年年度报告为准。 | 项目 | 本报告期 | 上年同期 | 变动比例% | | | --- | --- | --- | --- | --- | | 营业收入 | 442,160,238.66 | 424,129,063.73 | | 4.25% | | 归属于上市公司股 东的净利润 | 100,880,256.60 | 80,105,220.08 | | 25.93% | ...

梓橦宫 证券代码 : 832566 1 四川梓橦宫药业股份有限公司 2022 年第三季度报告 | 第一节 | 重要提示 4 | | --- | --- | | 第二节 | 公司基本情况 5 | | 第三节 | 重大事件 10 | | 第四节 | 财务会计报告 111 | 3 释义 释义项目 释义 公司、本公司、梓橦宫药业 指 四川梓橦宫药业股份有限公司 股东大会 指 四川梓橦宫药业股份有限公司股东大会 董事会 指 四川梓橦宫药业股份有限公司董事会 监事会 指 四川梓橦宫药业股份有限公司监事会 北交所 指 北京证券交易所 平安证券 指 平安证券股份有限公司 高级管理人员 指 总经理、副总经理、研发总监、财务负责人、董事会 秘书的统称 报告期 指 2022 年 7 月 1 日至 2022 年 9 月 30 日 元、万元 指 人民币元、万元 第一节 重要提示 公司董事、监事、高级管理人员保证本报告所载资料不存在虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担个别及连带责任。 公司负责人唐铣、主管会计工作负责人段立平及会计机构负责人（会计主管人员）余羚梦保证季度 报告中财务报告的真实、准确、 ...

Financial Performance - The company's revenue for the current period is CNY 203,345,251.46, representing a 2.93% increase compared to CNY 197,551,996.18 in the same period last year [28]. - The net profit attributable to shareholders is CNY 54,497,813.55, which is a 43.24% increase from CNY 38,045,955.13 year-on-year [28]. - The gross profit margin improved to 81.13% from 80.48% in the previous year [28]. - Total assets increased by 4.44% to CNY 811,068,182.75, up from CNY 776,603,783.55 at the end of the previous year [29]. - The total liabilities rose by 13.12% to CNY 146,711,492.08, compared to CNY 129,700,690.14 at the end of the previous year [29]. - The net cash flow from operating activities increased by 67.67% to CNY 35,896,446.85 from CNY 21,408,442.39 in the previous year [30]. - The weighted average return on equity based on net profit attributable to shareholders decreased to 8.21% from 9.59% [28]. - The basic earnings per share decreased by 44.78% to CNY 0.37 from CNY 0.67 in the previous year [28]. - The company achieved operating revenue of ¥203,345,251.46, a year-on-year increase of 2.93% [39]. - Net profit attributable to the listed company reached ¥54,497,813.55, reflecting a growth of 43.24% compared to the previous year [39]. Investment and R&D - The company has a total of 95 drug production approval numbers, focusing on the central nervous system and digestive system medications [34]. - The company plans to expand its product offerings in the fields of central nervous system and endocrine system medications [34]. - The company holds 44 patents, including 26 invention patents, and has a research team of over 50 members [39]. - The company established a new R&D company with an investment of ¥6,000,000 to enhance its innovation capabilities [39]. - The company has invested CNY 98,163,669.81 in new drug research and development, achieving 28.29% of the planned investment [96]. - Research and development expenses for the first half of 2022 were CNY 5,923,227.26, down from CNY 7,686,789.60 in the same period of 2021, indicating a decrease of approximately 22.93% [120]. Market and Competition - The pharmaceutical industry is facing intensified competition and challenges due to the ongoing COVID-19 pandemic and government control measures [41]. - The company is focusing on the market promotion of its new product, pregabalin oral solution, ahead of its launch [40]. - Revenue from the product "Alkaloid Sodium" increased by 4.30% to 186.12 million yuan, with a gross margin of 85.83% [54]. - Revenue from the South China region grew by 33.00%, driven by the company's efforts to develop large private hospitals in Guangdong [58]. Risk Management - The company faces risks related to new product development, including high costs and the potential for research failures, which could adversely affect future growth [12]. - The company is exposed to product price fluctuation risks due to national healthcare reforms and centralized procurement policies, which may impact profitability [12]. - The company has not experienced significant changes in major risks during the reporting period [13]. - The company has not faced any delisting risks as of the reporting date [13]. - The company’s production and sales were affected by the COVID-19 pandemic, but no significant adverse consequences were reported [13]. Corporate Governance - The company’s legal representative is Tang Xi, and the board secretary is Zeng Peiyu [19]. - The company has a total of 7 board members and 3 supervisory board members, with no changes in the chairman or general manager positions [107]. - The company appointed a new independent director, Huang Yuanlin, to meet development needs, following the resignation of former independent director Duan Xiaoqun [108]. - The total number of independent directors is now 3, following the recent changes [108]. - The company has not implemented any stock incentive plans during the reporting period [110]. Shareholder Information - The total share capital increased from 73,280,540 shares to 146,561,080 shares after the cash dividend distribution of 36,640,270.00 yuan and capital reserve conversion [85]. - The largest shareholder, Tang Xi, holds 32,925,730 shares, representing 22.47% of the total shares [88]. - The top ten shareholders collectively hold 75,568,074 shares, accounting for 51.56% of the total shares [88]. - The total number of common shareholders is 8,563 [84]. - Tang Xi directly controls 22.47% and indirectly controls an additional 1.45% of the company's shares, totaling 23.92% [90]. Cash Flow and Financial Position - Cash and cash equivalents decreased by 55.71% compared to the end of the previous year, primarily due to an increase in the amount of bank wealth management products purchased, totaling 280 million yuan at the end of the reporting period [47]. - The net cash flow from financing activities was negative at ¥36,651,262.07, attributed to the distribution of cash dividends amounting to ¥36,640,300, which was not present in the previous period [60]. - The total amount invested in financial products reached ¥1,131,957,957, with an unexpired balance of ¥280,417,957, and no overdue amounts reported [62]. - The company reported a significant decrease in credit impairment losses by 626.99%, reflecting improved management of accounts receivable [50]. - The company’s cash and cash equivalents at the end of the period totaled ¥66,154,072.65, down from ¥149,359,002.06 at the beginning of the period, representing a decrease of approximately 55.8% [194]. Environmental and Social Responsibility - The company is actively involved in poverty alleviation and rural revitalization efforts, including the establishment of a traditional Chinese medicine planting experimental base [68]. - The company has been recognized for its commitment to corporate social responsibility, including employee rights protection and community engagement initiatives [68]. - Environmental protection measures are in place, with the company being classified as a key pollutant discharge unit and having obtained necessary permits for waste discharge [69]. - The company has implemented effective measures to ensure compliance with environmental standards, with no reported exceedances in pollutant discharge limits [70]. Compliance and Legal Matters - No major litigation or arbitration matters reported during the reporting period [78]. - No funds, assets, or resources were occupied or transferred by shareholders or related parties during the reporting period [78]. - The actual controller and major shareholders are fulfilling their commitments regarding stock lock-up and stability measures [79]. - The company has made commitments to avoid related party transactions and ensure independent business operations [81].

Revenue Performance - The company's revenue from Choline Phosphate reached ¥383,467,775.06, with a gross margin of 85.67%, representing a year-on-year increase of 19.70%[4] - Revenue from Eastern Stomach Medicine was ¥9,852,934.85, with a gross margin of 58.89%, showing a decrease compared to the previous year's 47.48%[4] - Revenue from other pharmaceuticals decreased to ¥29,869,674.55, with a gross margin of 22.61%, reflecting a year-on-year decline of 21.09%[8] Customer Concentration - Total sales to major customers amounted to ¥264,971,347.35, accounting for 62.47% of the annual sales, with the largest customer being China National Pharmaceutical Group, contributing ¥123,793,246.63 or 29.19%[10] - The report indicates a significant reliance on a few major customers, with the top three customers accounting for over 50% of total sales[10] Financial Corrections - The company acknowledged the correction of financial data in its 2021 annual report, ensuring the accuracy and completeness of the information disclosed[2] - The company expressed apologies for any inconvenience caused to investors due to the corrections made in the financial report[10] Operational Insights - The company reported a total operating cost of ¥54,962,314.74 for Choline Phosphate, resulting in a gross profit of ¥328,505,460.32[4] - The company plans to maintain its current strategies while addressing the discrepancies found in the previous report[2] - The overall financial performance indicates a mixed trend, with some products showing growth while others experienced declines in revenue and gross margin[4]

Financial Performance - Net profit attributable to shareholders rose by 83.70% to CNY 28,401,290.54 for the first quarter of 2022, up from CNY 15,460,416.59 in the same period last year[19] - Operating revenue for the first quarter of 2022 was CNY 101,980,920.45, reflecting a growth of 10.75% compared to CNY 92,079,780.70 in the previous year[17] - Basic earnings per share increased by 44.44% to CNY 0.39 from CNY 0.27 year-on-year[17] - The company reported a net cash flow from operating activities of CNY 28,032,913.92, which is a 16.12% increase from CNY 24,142,159.26 in the same period last year[17] - The total non-recurring gains and losses amounted to CNY 14,470,310.98 after tax, contributing to the significant increase in net profit[21] - Operating revenue for Q1 2022 reached ¥101.98 billion, compared to ¥92.08 billion in Q1 2021, marking an increase of about 10.5%[41] - Operating profit for Q1 2022 was ¥37,078,044.98, compared to ¥18,518,193.30 in Q1 2021, marking an increase of 100.4%[45] - Total profit for Q1 2022 amounted to ¥36,711,050.78, up from ¥18,630,964.50 in Q1 2021, an increase of 96.9%[45] - Net profit for Q1 2022 was ¥30,951,503.77, representing a 95.5% increase from ¥15,836,319.82 in Q1 2021[46] Assets and Liabilities - Total assets increased by 7.43% to CNY 834,270,373.27 as of March 31, 2022, compared to CNY 776,603,783.55 at the end of 2021[17] - The asset-liability ratio (consolidated) increased to 19.10% from 16.70% year-on-year[17] - Total liabilities rose to ¥159.32 billion, up from ¥129.70 billion, indicating an increase of about 22.8%[35] - Total equity increased to ¥674.95 billion from ¥646.90 billion, reflecting a growth of approximately 4.3%[35] Cash Flow - Operating cash inflow for Q1 2022 was CNY 132,168,802.79, an increase of 24.6% compared to CNY 106,067,068.57 in Q1 2021[47] - Cash inflow from investment activities in Q1 2022 totaled CNY 521,711,482.17, significantly higher than CNY 127,580,160.43 in Q1 2021, marking a 309.5% increase[48] - Cash and cash equivalents at the end of Q1 2022 stood at CNY 128,878,593.72, compared to a negative balance of CNY -19,715,778.26 in Q1 2021[48] - The company reported a net increase in cash and cash equivalents of CNY 6,719,591.66 in Q1 2022, contrasting with a decrease of CNY -58,179,350.47 in Q1 2021[48] Shareholder Information - The total registered capital of the company is CNY 73,280,540[14] - The total number of shares held by major shareholders is 37,855,289, representing 51.65% of the total shares[26] - The largest shareholder, Tang Xi, holds 16,462,865 shares, accounting for 22.47% of the total shares[25] Expenses - Operating costs for Q1 2022 were ¥85.08 billion, up from ¥76.15 billion in Q1 2021, which is an increase of approximately 11.5%[41] - Research and development expenses decreased significantly to ¥375,692.08 in Q1 2022 from ¥5,475,719.95 in Q1 2021, a reduction of approximately 93.2%[45] - Sales expenses increased to ¥57,230,035.56 in Q1 2022, up from ¥44,406,536.48 in Q1 2021, reflecting a rise of 28.9%[44] - Tax expenses for Q1 2022 were ¥5,759,547.01, compared to ¥2,794,644.68 in Q1 2021, reflecting an increase of 106.4%[46] Other Financial Metrics - The weighted average return on equity based on net profit attributable to shareholders was 4.33%, up from 4.01% in the previous year[17] - The company disposed of idle properties and land, generating a gain of CNY 13,007,816.10, which positively impacted net profit[19] - Other income for Q1 2022 was ¥2,547,497.77, up from ¥1,278,838.90 in Q1 2021, an increase of 99.5%[45] - Investment income for Q1 2022 was ¥1,796,382.17, compared to ¥547,321.13 in Q1 2021, an increase of 228.5%[45] Legal and Corporate Actions - There were no significant legal disputes or external guarantees reported during the reporting period[29] - The company has not implemented any profit distribution or capital increase plans during the reporting period[30]

Financial Performance - Net profit attributable to shareholders increased by 83.70% to CNY 28,401,290.54 year-on-year[19] - Operating income rose by 10.75% to CNY 101,980,920.45 compared to the same period last year[19] - Basic earnings per share increased by 44.44% to CNY 0.39 compared to CNY 0.27 in the same period last year[17] - The company achieved a net cash flow from operating activities of CNY 28,032,913.92, up 16.12% year-on-year[17] - The company's operating profit for Q1 2022 was ¥37,078,044.98, compared to ¥18,518,193.30 in Q1 2021, marking an increase of 100%[44] - The net profit attributable to the parent company for Q1 2022 was ¥28,401,290.54, up 84% from ¥15,460,416.59 in Q1 2021[42] - The total profit for Q1 2022 was ¥36,711,050.78, compared to ¥18,630,964.50 in Q1 2021, reflecting a growth of 97%[44] - The total comprehensive income for Q1 2022 was ¥30,951,503.77, compared to ¥15,836,319.82 in Q1 2021, reflecting a growth of 95%[45] Assets and Liabilities - Total assets increased by 7.43% to CNY 834,270,373.27 compared to the end of the previous year[17] - The company's total liabilities to assets ratio (consolidated) increased to 19.10% from 16.70% at the end of the previous year[17] - The net assets attributable to shareholders increased by 4.42% to CNY 670,810,145.92 compared to the end of the previous year[17] - Total liabilities rose to CNY 159,322,919.75 from CNY 129,700,690.14, an increase of about 22.8%[34] - Total equity increased to CNY 674,947,453.52 from CNY 646,903,093.41, reflecting a growth of approximately 4.3%[34] - The total current assets reached ¥569,671,288.40, an increase from ¥507,829,146.22 in the previous period[32] - The company's trading financial assets rose to ¥201,837,957.00, compared to ¥162,630,000.00 in the previous period[32] Cash Flow - Cash and cash equivalents increased to CNY 180,852,185.06 from CNY 145,753,002.76, a growth of about 24.1%[36] - Operating cash inflow for Q1 2022 was CNY 132,168,802.79, an increase of 24.6% compared to CNY 106,067,068.57 in Q1 2021[46] - Cash inflow from investment activities in Q1 2022 totaled CNY 521,711,482.17, significantly higher than CNY 127,580,160.43 in Q1 2021, marking a 309.5% increase[47] - The company reported a net cash inflow of CNY 12,386,162.41 from operating activities in Q1 2022, compared to a net outflow of CNY -52,964,694.73 in Q1 2021[49] - The company achieved a net cash flow from operating activities of CNY 32,626,515.24 in Q1 2022, compared to CNY 26,408,355.00 in Q1 2021, reflecting a growth of 23.5%[49] Shareholder Information - The total number of shares held by the top ten shareholders is 37,855,289, representing 51.65% of the total shares[25] - The largest shareholder, Tang Xi, holds 16,462,865 shares, accounting for 22.47% of the total shares[25] Other Financial Metrics - The total non-recurring gains and losses amounted to CNY 4,027,459.83, with a net amount after tax of CNY 3,413,667.30[20] - The weighted average return on net assets (attributable to shareholders) increased to 4.33% from 4.01% year-on-year[17] - Research and development expenses decreased significantly to ¥375,692.08 in Q1 2022 from ¥5,475,719.95 in Q1 2021, indicating a strategic shift in R&D investment[44] - The sales expenses for Q1 2022 were ¥57,230,035.56, an increase from ¥44,406,536.48 in Q1 2021, indicating increased marketing efforts[44] - The tax expenses for Q1 2022 were ¥5,759,547.01, compared to ¥2,794,644.68 in Q1 2021, reflecting higher profitability[44]